PULMONARY ARTERIAL HYPERTENSION
Clinical trials for PULMONARY ARTERIAL HYPERTENSION explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ARTERIAL HYPERTENSION trials appear
Sign up with your email to follow new studies for PULMONARY ARTERIAL HYPERTENSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for PAH patients? india study tests sotatercept safety
Disease control Not yet recruitingThis study tests the safety of a new medicine called sotatercept for adults in India with pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs become narrow, making breathing hard. About 30 people will receive sotatercept along with their usual trea…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE4 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a simple supplement ease a rare lung disease?
Disease control Not yet recruitingThis phase 2 trial tests a dietary supplement called 2-HOBA in 12 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs strains the heart. Participants take the supplement three times daily for 12 weeks. The study checks if 2-HOBA i…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug hopes to ease rare lung condition in children
Disease control Not yet recruitingThis study tests the safety and tolerability of sotatercept in Japanese children aged 1 to 18 with pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs narrow, making the heart work harder. Participants receive sotatercept injections every three wee…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New PAH drug IKT-001 moves to Long-Term safety check
Disease control Not yet recruitingThis study is checking the long-term safety of a daily pill called IKT-001 for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 484 adults who have already completed an earlier IKT-001 study will take the drug for an extended period. Researchers …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE3 • Sponsor: Inhibikase Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New antibody aims to tame rare bleeding disorder
Disease control Not yet recruitingThis early-phase trial tests an experimental antibody called DIAG723 in 93 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The study will check if the drug is safe and how the body processes it, with…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE1, PHASE2 • Sponsor: Diagonal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for PAH patients: Extended-Release tacrolimus enters phase 3 trial
Disease control Not yet recruitingThis Phase 3 study tests VI-0106, an extended-release form of tacrolimus, in 300 people with pulmonary arterial hypertension (PAH) who still have trouble with daily activities despite taking standard PAH medications. Participants will receive either the drug or a placebo for 24 w…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE3 • Sponsor: VIVUS LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill could ease rare lung disease
Disease control Not yet recruitingThis Phase 2 trial tests an oral drug called NS-863 in 135 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goa…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New scan could spot hidden scarring in heart and lungs before It's too late
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 18F-FAPI-74 that may help detect scar tissue (fibrosis) in the heart and lungs earlier than current methods. Researchers will compare this new PET/CT scan to standard imaging in 210 adults with conditions like lung disease or heart…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE3 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Diagnosis
Last updated Jul 01, 2026 23:00 UTC
-
Sleep trouble linked to heart risk in lung disease patients
Knowledge-focused Not yet recruitingThis study follows 60 adults with pulmonary hypertension (high blood pressure in the lungs) for 2 years. Researchers will measure breathing problems during sleep and heart rate changes to see how they relate to the disease. No new treatment is given; participants continue their u…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Tiny study aims to unlock clues in rare lung disease
Knowledge-focused Not yet recruitingThis study looks at how changes in the cells lining blood vessels relate to lung resistance in people with pulmonary artery hypertension (PAH). Researchers will measure certain blood markers and lung pressure in 6 adults with PAH. The goal is to better understand the disease, not…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: NA • Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Small study explores real-world switch to riociguat for tough PAH cases
Knowledge-focused Not yet recruitingThis observational study will review medical records of 15 adults with pulmonary arterial hypertension (PAH) who switched from one medication (a PDE5 inhibitor) to riociguat while already on triple therapy. The goal is to see if this switch improves exercise ability, symptoms, an…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Caio Júlio César dos Santos Fernandes • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC